Invictus announces Closing of Non-Brokered Private Placement
July 09 2019 - 9:52AM
Vancouver, BC, July 9, 2019 – INVICTUS MD STRATEGIES CORP.
(“Invictus” or the “Company”) (TSXV: GENE; OTCQX: IVITF; FRA:
8IS2) announces it has closed the non-brokered private
placement consisting of 1,250,000 units at a price of $0.40 per
unit to raise $500,000 announced on July 3, 2019 (the "Private
Placement"). Each unit consists of one common share
of the Company and a one-half common share purchase warrant, with
each full warrant exercisable at $0.60 until July 9, 2021.
The proceeds of the Private Placement will primarily be used for
general working capital purposes.
On Behalf of the Board
Trevor Dixon
Chief Executive Officer
Investor Relations 1-844-800-6086
E-Mail: connect@invictus-md.com
About Invictus
Invictus is a global cannabis company with a focus on the
Canadian cannabis space, offering a selection of products under a
wide range of cannabinoid profiles that fit the demand of the
Company’s medical clients and retail customers. The Company’s
integrated sales approach is defined by five pillars of
distribution including medical, adult-use, international, Licensed
Producer to Licensed Producer and sales to provinces.
To meet growing demand, Invictus is expanding its cultivation
footprint with three cannabis production facilities licensed under
the Cannabis Act, which replaced the Access to Cannabis for Medical
Purposes Regulations in Canada. Invictus’ wholly-owned subsidiary,
Acreage Pharms Ltd.’s (“Acreage”) Phase I and Phase II
facilities are in full production and Acreage is completing its
Phase III cultivation facility. AB Laboratories Inc., a company
which is a 50% owned subsidiary of Invictus continues its
cultivation facility expansion. Invictus’ wholly owned subsidiary
0989561 B.C. Ltd. (dba Canandia Bioceuticals) Delta facility is a
licensed producer and has received its sales license issued by
Health Canada under the Cannabis Act. Another of Invictus’
wholly owned subsidiaries, 2015059 Alberta Ltd. (dba Leaf Wise),
continues to connect medical clients to physicians for medical
cannabis and to Invictus’ fully licensed cannabis producers under
the Cannabis Act. Future Harvest Development Ltd., a company
which is a 82.5% owned subsidiary of Invictus continues to produce
high-quality fertilizer and nutrients which are supplied to
licensed cannabis producers. Invictus is targeting up to 50 percent
of production to medical cannabis. Invictus drives sustainable
long-term shareholder value by continuing to develop Invictus’
Canadian production of medical and recreational cannabis products.
For more information visit www.invictus-md.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
Kathy Love
Invictus
kathy@invictus-md.com
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Sep 2023 to Sep 2024